The stigma scale for chronic illnesses 8-item version (SSCI-8): development, validation and use across neurological conditions.
The stigma scale for chronic illnesses 8-item version (SSCI-8): development, validation and use across neurological conditions.
复制标题
DOI：
10.1007/s12529-012-9243-4
复制
发表时间：
2013-09
影响因子：
2.7
通讯作者：
Rao D
中科院分区：
文献类型：
--
作者：
Molina Y;Choi SW;Cella D;Rao D
Although the impact of stigma has been highlighted for epileptic populations, the experiences of people living with other neurological conditions have been less studied. In order to promote research on stigma among people with neurological conditions, we sought to develop and psychometrically validate an 8-item questionnaire measuring internalised and enacted stigma experienced by people with epilepsy, multiple sclerosis (MS), Parkinson’s disease (PD), stroke, and amyotrophic lateral sclerosis (ALS). We used Item Response Theory (IRT) methodologies to select items and field-tested our items with 587 participants from 8 academic medical centres across the United States. We conducted Exploratory and Confirmatory Factor Analysis as well as examined scale the reliability and validity. In addition, we conducted an analysis of variance (ANOVA) test to examine mean total score differences across the 5 neurological conditions. Data from people across conditions revealed that the shortened instrument conformed to an essentially unidimensional model of multi-faceted stigma as a 1-factor questionnaire with correlated residuals on a pair of items that distinctly measured internalised stigma. Preliminary evidence suggests that the Stigma Scale for Chronic Illness 8-item version (SSCI-8) fits a unidimensional model, which assesses enacted and internalised stigma, and has adequate internal consistency/reliability and validity in relation to psychological distress and patient performance. Our results suggest fairly low stigma for neurological populations. In addition, our results suggest that stigma may be more severe for patients with ALS relative to those with MS and PD. Our results suggest that the scale could be used practically in the clinic setting to examine stigma without the patient burden associated with lengthier scales.
登录
查看更多内容
影响因子：
2.6
作者：
Kumari, Pallavi;Ram, Daya;Goyal, Nishant
通讯作者：
Goyal, Nishant
影响因子：
1.7
作者：
Corrigan, Patrick W.;Watson, Amy C.;Barr, Leah
通讯作者：
Barr, Leah
影响因子：
6
作者：
Jenkinson, C;Fitzpatrick, R;Peto, V
通讯作者：
Peto, V
影响因子：
5.6
作者：
Harden, CL;Kossoy, A;Nikolov, B
通讯作者：
Nikolov, B
影响因子：
1.5
作者：
Kang, Sung Ye
通讯作者：
Kang, Sung Ye